China’s National Healthcare Security Administration announced that relma-cel, a CAR-T cell therapy developed by JW Therapeutics, will be included in the basic medical insurance system starting Jan. 1, marking the first time this type of therapy has entered China’s national medical insurance coverage. The therapy has been approved for three types of lymphoma, with a price of 1.29 million yuan per dose; as of the end of 2025, China’s basic medical insurance program had 1.33 billion insured participants. Before inclusion in the medical insurance system, patients typically had to pay the full cost of medicines not listed in the medical insurance catalog.
Source:Fresh voices from today's China · Read Original
Leave a Reply